Literature DB >> 22101830

IL-23-dependent IL-17 drives Th1-cell responses following Mycobacterium bovis BCG vaccination.

Radha Gopal1, Yinyao Lin, Nataša Obermajer, Samantha Slight, Nikhil Nuthalapati, Mushtaq Ahmed, Pawel Kalinski, Shabaana A Khader.   

Abstract

The generation of effective type 1 T helper (Th1)-cell responses is required for immunity against intracellular bacteria. However, some intracellular bacteria require interleukin (IL)-17 to drive Th1-cell immunity and subsequent protective host immunity. Here, in a model of Mycobacterium bovis Bacille Calmette-Guerin (BCG) vaccination in mice, we demonstrate that the dependence on IL-17 to drive Th1-cell responses is a host mechanism to overcome bacteria-induced IL-10 inhibitory effects. We show that BCG-induced prostaglandin-E2 (PGE2) promotes the production of IL-10 which limits Th1-cell responses, while simultaneously inducing IL-23 and Th17-cell differentiation. The ability of IL-17 to downregulate IL-10 and induce IL-12 production allows the generation of subsequent Th1-cell responses. Accordingly, BCG-induced Th17-cell responses precede the generation of Th1-cell responses in vivo, whereas the absence of the IL-23 pathway decreases BCG vaccine-induced Th17 and Th1-cell immunity and subsequent vaccine-induced protection upon M. tuberculosis challenge. Importantly, in the absence of IL-10, BCG-induced Th1-cell responses occur in an IL-17-independent manner. These novel data demonstrate a role for the IL-23/IL-17 pathway in driving Th1-cell responses, specifically to overcome IL-10-mediated inhibition and, furthermore, show that in the absence of IL-10, the generation of BCG-induced Th1-cell immunity is IL-17 independent.
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22101830      PMCID: PMC3490408          DOI: 10.1002/eji.201141569

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  38 in total

1.  Regulatory activity of autocrine IL-10 on dendritic cell functions.

Authors:  S Corinti; C Albanesi; A la Sala; S Pastore; G Girolomoni
Journal:  J Immunol       Date:  2001-04-01       Impact factor: 5.422

2.  Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer.

Authors:  P Kaliński; P L Vieira; J H Schuitemaker; E C de Jong; M L Kapsenberg
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

3.  Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.

Authors:  B Oppmann; R Lesley; B Blom; J C Timans; Y Xu; B Hunte; F Vega; N Yu; J Wang; K Singh; F Zonin; E Vaisberg; T Churakova; M Liu; D Gorman; J Wagner; S Zurawski; Y Liu; J S Abrams; K W Moore; D Rennick; R de Waal-Malefyt; C Hannum; J F Bazan; R A Kastelein
Journal:  Immunity       Date:  2000-11       Impact factor: 31.745

4.  Autocrine IL-10 impairs dendritic cell (DC)-derived immune responses to mycobacterial infection by suppressing DC trafficking to draining lymph nodes and local IL-12 production.

Authors:  Caroline Demangel; Patrick Bertolino; Warwick J Britton
Journal:  Eur J Immunol       Date:  2002-04       Impact factor: 5.532

5.  Influence of interleukin-12 receptor beta1 polymorphisms on tuberculosis.

Authors:  Mitsuteru Akahoshi; Hitoshi Nakashima; Katsuhisa Miyake; Yasushi Inoue; Sakiko Shimizu; Yosuke Tanaka; Kaoru Okada; Takeshi Otsuka; Mine Harada
Journal:  Hum Genet       Date:  2002-12-13       Impact factor: 4.132

Review 6.  Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis.

Authors:  Christopher Dye; Brian G Williams; Marcos A Espinal; Mario C Raviglione
Journal:  Science       Date:  2002-03-15       Impact factor: 47.728

7.  Enhanced protection to Mycobacterium tuberculosis infection in IL-10-deficient mice is accompanied by early and enhanced Th1 responses in the lung.

Authors:  Paul S Redford; Andre Boonstra; Simon Read; Jonathan Pitt; Christine Graham; Evangelos Stavropoulos; Gregory J Bancroft; Anne O'Garra
Journal:  Eur J Immunol       Date:  2010-08       Impact factor: 5.532

8.  Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells.

Authors:  Beatrice Schuler-Thurner; Erwin S Schultz; Thomas G Berger; Georg Weinlich; Susanne Ebner; Petra Woerl; Armin Bender; Bernadette Feuerstein; Peter O Fritsch; Nikolaus Romani; Gerold Schuler
Journal:  J Exp Med       Date:  2002-05-20       Impact factor: 14.307

9.  Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma.

Authors:  B Thurner; I Haendle; C Röder; D Dieckmann; P Keikavoussi; H Jonuleit; A Bender; C Maczek; D Schreiner; P von den Driesch; E B Bröcker; R M Steinman; A Enk; E Kämpgen; G Schuler
Journal:  J Exp Med       Date:  1999-12-06       Impact factor: 14.307

10.  Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense.

Authors:  P Ye; F H Rodriguez; S Kanaly; K L Stocking; J Schurr; P Schwarzenberger; P Oliver; W Huang; P Zhang; J Zhang; J E Shellito; G J Bagby; S Nelson; K Charrier; J J Peschon; J K Kolls
Journal:  J Exp Med       Date:  2001-08-20       Impact factor: 14.307

View more
  81 in total

1.  A novel nanoemulsion vaccine induces mucosal Interleukin-17 responses and confers protection upon Mycobacterium tuberculosis challenge in mice.

Authors:  Mushtaq Ahmed; Douglas M Smith; Tarek Hamouda; Javier Rangel-Moreno; Ali Fattom; Shabaana A Khader
Journal:  Vaccine       Date:  2017-07-31       Impact factor: 3.641

2.  Polyclonal mucosa-associated invariant T cells have unique innate functions in bacterial infection.

Authors:  Wei-Jen Chua; Steven M Truscott; Christopher S Eickhoff; Azra Blazevic; Daniel F Hoft; Ted H Hansen
Journal:  Infect Immun       Date:  2012-07-09       Impact factor: 3.441

3.  mTORC2 Deficiency in Myeloid Dendritic Cells Enhances Their Allogeneic Th1 and Th17 Stimulatory Ability after TLR4 Ligation In Vitro and In Vivo.

Authors:  Dàlia Raïch-Regué; Brian R Rosborough; Alicia R Watson; Mandy J McGeachy; Hēth R Turnquist; Angus W Thomson
Journal:  J Immunol       Date:  2015-04-03       Impact factor: 5.422

4.  Eicosanoids, prostaglandins, and the progression of tuberculosis.

Authors:  Deepak Kaushal
Journal:  J Infect Dis       Date:  2012-10-02       Impact factor: 5.226

5.  IL12B expression is sustained by a heterogenous population of myeloid lineages during tuberculosis.

Authors:  Allison E Reeme; Halli E Miller; Richard T Robinson
Journal:  Tuberculosis (Edinb)       Date:  2013-03-13       Impact factor: 3.131

Review 6.  The crucial roles of Th17-related cytokines/signal pathways in M. tuberculosis infection.

Authors:  Hongbo Shen; Zheng W Chen
Journal:  Cell Mol Immunol       Date:  2017-11-27       Impact factor: 11.530

Review 7.  Quest for correlates of protection against tuberculosis.

Authors:  Kamlesh Bhatt; Sheetal Verma; Jerrold J Ellner; Padmini Salgame
Journal:  Clin Vaccine Immunol       Date:  2015-01-14

8.  A novel multivalent tuberculosis vaccine confers protection in a mouse model of tuberculosis.

Authors:  Kristin L Griffiths; Daniel O Villarreal; David B Weiner; Shabaana A Khader
Journal:  Hum Vaccin Immunother       Date:  2016-06-20       Impact factor: 3.452

Review 9.  Th1 cytokines, true functional signatures for protective immunity against TB?

Authors:  Gucheng Zeng; Guoliang Zhang; Xinchun Chen
Journal:  Cell Mol Immunol       Date:  2017-11-20       Impact factor: 11.530

10.  Endogenous interleukin (IL)-17A promotes pristane-induced systemic autoimmunity and lupus nephritis induced by pristane.

Authors:  S A Summers; D Odobasic; M B Khouri; O M Steinmetz; Y Yang; S R Holdsworth; A R Kitching
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.